Combining the CD19–4-1BBL co-stimulatory molecule englumafusp alfa with the bispecific antibody glofitamab in patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma showed acceptable safety signals and encouraging preliminary clinical responses, with mechanistic data supporting the rational choice of therapy.